This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026, SEC filing. What happened According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management reduced its holding in Viridian Therapeutics by 2,957,386 shares during the fourth quarter. The estimated transaction value is $81.11 million, calculated using the average closing price for the quarter. The value of the Viridian stake at quarter-end declined by $49.79 million, a figure that includes both trading and market price effects. What else to know The fund sold shares, bringing its Viridian stake to 2.92% of 13F reportable assets under management. Top five holdings after the filing: NASDAQ:COGT: $218.99 million (14.3% of AUM) NASDAQ:VERA: $173.85 million (11.3% of AUM) NASDAQ:SNDX: $169.15 million (11.0% of AUM) NASDAQ:CLDX: $161.42 million (10.5% of AUM) NASDAQ:PCV
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.MarketBeat
- What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 3/9/26 - Form 4/A
- 3/9/26 - Form 4/A
- 3/9/26 - Form 4/A
- VRDN's page on the SEC website